Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3b long-term safety and efficacy study of garadacimab for prophylaxis in hereditary angioedema
MOH_2021-05-11_009967Phase 3Recruiting
- Sponsor
- CSL Behring
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of garadacimab in hereditary angioedema (HAE) (2 arms), sponsored by CSL Behring. Started Apr 2021; status: recruiting.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2021-05-11_009967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-11_009967.